These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
769 related articles for article (PubMed ID: 33005627)
1. Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) - Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy. Harrision D; Gravells P; Thompson R; Bryant HE Front Mol Biosci; 2020; 7():191. PubMed ID: 33005627 [TBL] [Abstract][Full Text] [Related]
2. Specific killing of DNA damage-response deficient cells with inhibitors of poly(ADP-ribose) glycohydrolase. Gravells P; Grant E; Smith KM; James DI; Bryant HE DNA Repair (Amst); 2017 Apr; 52():81-91. PubMed ID: 28254358 [TBL] [Abstract][Full Text] [Related]
3. Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib. Gravells P; Neale J; Grant E; Nathubhai A; Smith KM; James DI; Bryant HE DNA Repair (Amst); 2018 Jan; 61():25-36. PubMed ID: 29179156 [TBL] [Abstract][Full Text] [Related]
5. Altered poly(ADP-ribose) metabolism impairs cellular responses to genotoxic stress in a hypomorphic mutant of poly(ADP-ribose) glycohydrolase. Gao H; Coyle DL; Meyer-Ficca ML; Meyer RG; Jacobson EL; Wang ZQ; Jacobson MK Exp Cell Res; 2007 Mar; 313(5):984-96. PubMed ID: 17276427 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP‑ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells. Feng X; Koh DW Int J Oncol; 2013 Feb; 42(2):749-56. PubMed ID: 23254695 [TBL] [Abstract][Full Text] [Related]
7. Disrupted ADP-ribose metabolism with nuclear Poly (ADP-ribose) accumulation leads to different cell death pathways in presence of hydrogen peroxide in procyclic Trypanosoma brucei. Schlesinger M; Vilchez Larrea SC; Haikarainen T; Narwal M; Venkannagari H; Flawiá MM; Lehtiö L; Fernández Villamil SH Parasit Vectors; 2016 Mar; 9():173. PubMed ID: 27007296 [TBL] [Abstract][Full Text] [Related]
8. Deletion of the nuclear isoform of poly(ADP-ribose) glycohydrolase (PARG) reveals its function in DNA repair, genomic stability and tumorigenesis. Min W; Cortes U; Herceg Z; Tong WM; Wang ZQ Carcinogenesis; 2010 Dec; 31(12):2058-65. PubMed ID: 20926829 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents. Matanes E; López-Ozuna VM; Octeau D; Baloch T; Racovitan F; Dhillon AK; Kessous R; Raban O; Kogan L; Salvador S; Lau S; Gotlieb WH; Yasmeen A Front Oncol; 2021; 11():745981. PubMed ID: 34778062 [TBL] [Abstract][Full Text] [Related]
10. Spatial and functional relationship between poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in the brain. Poitras MF; Koh DW; Yu SW; Andrabi SA; Mandir AS; Poirier GG; Dawson VL; Dawson TM Neuroscience; 2007 Aug; 148(1):198-211. PubMed ID: 17640816 [TBL] [Abstract][Full Text] [Related]
11. A quantitative assay reveals ligand specificity of the DNA scaffold repair protein XRCC1 and efficient disassembly of complexes of XRCC1 and the poly(ADP-ribose) polymerase 1 by poly(ADP-ribose) glycohydrolase. Kim IK; Stegeman RA; Brosey CA; Ellenberger T J Biol Chem; 2015 Feb; 290(6):3775-83. PubMed ID: 25477519 [TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose) accumulation and enhancement of postischemic brain damage in 110-kDa poly(ADP-ribose) glycohydrolase null mice. Cozzi A; Cipriani G; Fossati S; Faraco G; Formentini L; Min W; Cortes U; Wang ZQ; Moroni F; Chiarugi A J Cereb Blood Flow Metab; 2006 May; 26(5):684-95. PubMed ID: 16177811 [TBL] [Abstract][Full Text] [Related]
13. PARP and PARG inhibitors in cancer treatment. Slade D Genes Dev; 2020 Mar; 34(5-6):360-394. PubMed ID: 32029455 [TBL] [Abstract][Full Text] [Related]
14. Mitotic functions of poly(ADP-ribose) polymerases. Slade D Biochem Pharmacol; 2019 Sep; 167():33-43. PubMed ID: 30910692 [TBL] [Abstract][Full Text] [Related]
15. Discovery and structure-activity relationships of modified salicylanilides as cell permeable inhibitors of poly(ADP-ribose) glycohydrolase (PARG). Steffen JD; Coyle DL; Damodaran K; Beroza P; Jacobson MK J Med Chem; 2011 Aug; 54(15):5403-13. PubMed ID: 21692479 [TBL] [Abstract][Full Text] [Related]
16. Synergistic Effect of Ubiquitin-Specific Protease 14 and Poly(ADP-Ribose) Glycohydrolase Co-Inhibition in BRCA1-Mutant, Poly(ADP-Ribose) Polymerase Inhibitor-Resistant Triple-Negative Breast Cancer Cells. Li P; Zhu X; Qu H; Han Z; Yao X; Wei Y; Li B; Chen H Onco Targets Ther; 2024; 17():741-753. PubMed ID: 39258222 [TBL] [Abstract][Full Text] [Related]
17. PARG Inhibitors and Functional PARG Inhibition Models. Sasaki Y; Hozumi M; Fujimori H; Murakami Y; Koizumi F; Inoue K; Masutani M Curr Protein Pept Sci; 2016; 17(7):641-653. PubMed ID: 27817742 [TBL] [Abstract][Full Text] [Related]
18. Global analysis of transcriptional regulation by poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in MCF-7 human breast cancer cells. Frizzell KM; Gamble MJ; Berrocal JG; Zhang T; Krishnakumar R; Cen Y; Sauve AA; Kraus WL J Biol Chem; 2009 Dec; 284(49):33926-38. PubMed ID: 19812418 [TBL] [Abstract][Full Text] [Related]